

Case Study | Harvard University

Conducting pathway analyses to accelerate discovery research

Before using MetaCore™, a Cortellis™ solution, researchers at Harvard University lacked an understanding of disease pathway versus biological pathway, and couldn't obtain the analyses needed in the required timeframe from their internal bioinformatics team.

Harvard University's main reasons for choosing MetaCore are its easiness of use, its manually curated content and that MetaCore indicates mechanism, directionality, and effect on over two million molecular interactions.

MetaCore has helped Harvard University to:



understand a drug's impact on a disease at the molecular level,



empower biologists to analyze their own data, which frees up the bioinformatics team,



have greater confidence in decisions by rapidly generating and validating hypotheses regarding targets, biomarkers, and pathways,



make critical go/no-go decisions regarding which drugs to push through the development lifecycle, by providing an understanding of omics data in the context of their therapeutic area,



save money by reducing efforts spent on unsuccessful research and



save more than five hours per week due to increased productivity.

"MetaCore gives me a reliable pathway enrichment analysis that you cannot usually obtain from conventional bioinformatic analysis. Additionally, upstream analysis is quite unique to MetaCore, which achieves further understanding of my RNA-seq data."

Motohiko Kadoki,
Postdoctoral Fellow, Harvard University

For more information on how MetaCore can accelerate innovation for your organization, visit our website at:

clarivate.com/cortellis

© 2020 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.

This case study is based on a March 2020 survey of MetaCore customers by a third-party research service.